According to the Cadila Healthcare's annual report for fiscal year
2019-20, the company is planning to introduce additional "topical,
transdermal and injectable products" in coming years. The US was the
largest contributor to the consolidated revenues of the company with
45 per cent share, it said.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-generics-business-to-continue-its-growth-momentum-pharma-firm-cadila-healthcare/articleshow/77312223.cms
No comments:
Post a Comment